IL2 and neuroblastoma: All children received induction chemotherapy, surgery, local irradiation, and autologous HSCT; then, patients were randomized to receive either five cycles of dinutuximab (3 in combination with GM-CSF and 2 with IL-2) and cis-retinoic acid (CRA) or CRA alone, a product favoring NB differentiation [38,39].